

**To:** Biggio, Patricia[biggio.patricia@epa.gov]; Nguyen, Khue[Nguyen.Khue@epa.gov]; Jones, Ricardo[Jones.Ricardo@epa.gov]; Newcamp, Caitlin[Newcamp.Caitlin@epa.gov]  
**Cc:** Anderson, Neil[Anderson.Neil@epa.gov]  
**From:** Grable, Melissa  
**Sent:** Tue 4/4/2017 7:16:44 PM  
**Subject:** FW: Chemical Review Meeting 4/20  
[FY17Q3 DRAs for registration review.docx](#)  
[Monthly Chemical Meeting\\_Q2\\_01\\_26\\_17\\_Final.pptx](#)

The next Program Review, which will focus on DRAs, will be on April 20th. While it is still very early in the quarter, we need to provide summaries of what we know about the risks for chemicals with Q3 DRAs (please see the attached list with the cases for which we expect risk assessments in Q3 and the CRM assigned to that case). Although in many cases we might not have real risk assessments yet, you all will need to contact the EFED and HED team members about what we do know at this time for each of these cases. Again, the focus would be on general risk picture and not necessarily specific numbers. Also attached to this email are the slides that we used last time there was a Program Review on DRAs early in the quarter, which can be used for an example. Basically, we are looking for one slide per chemical.

We need to get the slides together within the next week, so please get me your slides by the end of this week or by Monday, April 10<sup>th</sup> at the latest so I can review them.

Thanks,

Melissa

PS – Just a reminder that buprofezin moved from Q3 to Q4